Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Avandamet 2mg/500mg tablets
0601023V0BBABAB
|
Avandamet | Metformin hydrochloride/rosiglitazone | Endocrine System | 3 |
|
Avandamet 1mg/500mg tablets
0601023V0BBAAAA
|
Avandamet | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Avandamet 2mg/1000mg tablets
0601023V0BBADAD
|
Avandamet | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Avandamet 4mg/1000mg tablets
0601023V0BBACAC
|
Avandamet | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Rosiglitazone 1mg / Metformin 500mg tablets
0601023V0AAAAAA
|
Metformin hydrochloride/rosiglitazone | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Rosiglitazone 2mg / Metformin 1g tablets
0601023V0AAADAD
|
Metformin hydrochloride/rosiglitazone | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Rosiglitazone 2mg / Metformin 500mg tablets
0601023V0AAABAB
|
Metformin hydrochloride/rosiglitazone | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
|
Rosiglitazone 4mg / Metformin 1g tablets
0601023V0AAACAC
|
Metformin hydrochloride/rosiglitazone | Metformin hydrochloride/rosiglitazone | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.